Literature DB >> 12524402

Investigation of the putative immunodominant T cell epitopes in coeliac disease.

H J Ellis1, E L Pollock, W Engel, J S Fraser, S Rosen-Bronson, H Wieser, P J Ciclitira.   

Abstract

BACKGROUND: Coeliac disease (CD) is an enteropathy mediated by gluten specific T cells which secrete interferon gamma (IFN-gamma) when stimulated by gluten peptides presented by HLA-DQ2 or DQ8 molecules. Residues 62-75 of alpha(2) gliadin have been proposed as the immunodominant epitope in the majority of CD patients. Deamidation by tissue transglutaminase (tTG) of the glutamine (Q) at position 65 to glutamic acid (E) is essential for T cell stimulation. AIMS: To investigate the antigenicity of this peptide and to establish whether its T cell activating properties can be downregulated by the formation of altered peptide ligands. PATIENTS: Individuals with known CD.
METHODS: Peptide G4 corresponding to alpha(2) gliadin residues 62-75, Q-E65 and analogues, substituting each amino acid, except E65, in turn for alanine residues, were synthesised. Small intestinal biopsies were obtained from patients. Biopsies were cultured overnight with a peptic/tryptic digest of gliadin (PTG). Lymphocytes were cultured and restimulated with tTG treated PTG. A T cell line was cloned and clones tested for stimulation and IFN-gamma production in response to G4 and its analogues.
RESULTS: Some high activity clones were isolated with, for example, a stimulation index (SI) of 15 to G4 and secreting 327 pg/ml of IFN-gamma. Substitution of amino acids at several positions abolished or downregulated stimulation and IFN-gamma production.
CONCLUSIONS: Peptide G4 is highly immunogenic. Certain amino acid substitutions in peptide G4 abolish T cell reactivity while others are partial agonists which may have potential in immunomodulation in this condition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12524402      PMCID: PMC1774960          DOI: 10.1136/gut.52.2.212

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  31-43 amino acid sequence of the alpha-gliadin induces anti-endomysial antibody production during in vitro challenge.

Authors:  A Picarelli; M Di Tola; L Sabbatella; M C Anania; T Di Cello; R Greco; M Silano; M De Vincenzi
Journal:  Scand J Gastroenterol       Date:  1999-11       Impact factor: 2.423

2.  In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope.

Authors:  R P Anderson; P Degano; A J Godkin; D P Jewell; A V Hill
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

3.  Glutenin is involved in the gluten-driven mucosal T cell response.

Authors:  Y van de Wal; Y M Kooy; P van Veelen; W Vader; S A August; J W Drijfhout; S A Peña; F Koning
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

4.  Local challenge on oral mucosa with an alpha-gliadin related synthetic peptide in patients with celiac disease.

Authors:  H Lähteenoja; M Mäki; M Viander; I Räihä; P Vilja; I Rantala; A Toivanen; S Syrjänen
Journal:  Am J Gastroenterol       Date:  2000-10       Impact factor: 10.864

5.  T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase.

Authors:  O Molberg; S McAdam; K E Lundin; C Kristiansen; H Arentz-Hansen; K Kett; L M Sollid
Journal:  Eur J Immunol       Date:  2001-05       Impact factor: 5.532

Review 6.  Molecular basis of celiac disease.

Authors:  L M Sollid
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

7.  The peptide binding motif of the disease associated HLA-DQ (alpha 1* 0501, beta 1* 0201) molecule.

Authors:  F Vartdal; B H Johansen; T Friede; C J Thorpe; S Stevanović; J E Eriksen; K Sletten; E Thorsby; H G Rammensee; L M Sollid
Journal:  Eur J Immunol       Date:  1996-11       Impact factor: 5.532

8.  Coeliac disease: follow-up linkage study provides further support for existence of a susceptibility locus on chromosome 11p11.

Authors:  A L King; J S Fraser; S J Moodie; D Curtis; A M Dearlove; H J Ellis; S Rosen-Bronson; P J Ciclitira
Journal:  Ann Hum Genet       Date:  2001-07       Impact factor: 1.670

Review 9.  Celiac disease: strongly heritable, oligogenic, but genetically complex.

Authors:  A L King; P J Ciclitira
Journal:  Mol Genet Metab       Date:  2000 Sep-Oct       Impact factor: 4.797

10.  The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase.

Authors:  H Arentz-Hansen; R Körner; O Molberg; H Quarsten; W Vader; Y M Kooy; K E Lundin; F Koning; P Roepstorff; L M Sollid; S N McAdam
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

View more
  10 in total

1.  Gliadin peptide specific intestinal T cells in coeliac disease.

Authors:  K E A Lundin; L M Sollid
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

2.  Highly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for celiac disease.

Authors:  Carlo G Rizzello; Maria De Angelis; Raffaella Di Cagno; Alessandra Camarca; Marco Silano; Ilario Losito; Massimo De Vincenzi; Maria D De Bari; Francesco Palmisano; Francesco Maurano; Carmen Gianfrani; Marco Gobbetti
Journal:  Appl Environ Microbiol       Date:  2007-05-18       Impact factor: 4.792

3.  Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease.

Authors:  W Dieterich; B Esslinger; D Trapp; E Hahn; T Huff; W Seilmeier; H Wieser; D Schuppan
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

4.  Analysis of oat seed transcriptome with regards to proteins involved in celiac disease.

Authors:  Leona Leišová-Svobodová; Tereza Sovová; Václav Dvořáček
Journal:  Sci Rep       Date:  2022-05-23       Impact factor: 4.996

5.  Coeliac disease: immunogenicity studies of barley hordein and rye secalin-derived peptides.

Authors:  Widya A Wahab; Tanja Šuligoj; Julia Ellis; Beatriz Côrtez-Real; Paul J Ciclitira
Journal:  Int J Exp Pathol       Date:  2016-09-23       Impact factor: 1.925

6.  Coeliac disease: in vivo toxicity of the putative immunodominant epitope.

Authors:  J S Fraser; W Engel; H J Ellis; S J Moodie; E L Pollock; H Wieser; P J Ciclitira
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

7.  Two prolamin peptides from durum wheat preclude celiac disease-specific T cell activation by gluten proteins.

Authors:  Massimo De Vincenzi; Olimpia Vincentini; Giovanni Di Nardo; Monica Boirivant; Laura Gazza; Norberto Pogna
Journal:  Eur J Nutr       Date:  2009-11-06       Impact factor: 5.614

8.  Persistent changes in circulating and intestinal γδ T cell subsets, invariant natural killer T cells and mucosal-associated invariant T cells in children and adults with coeliac disease.

Authors:  Margaret R Dunne; Louise Elliott; Seamus Hussey; Nasir Mahmud; Jacinta Kelly; Derek G Doherty; Conleth F Feighery
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

Review 9.  Current and emerging therapy for celiac disease.

Authors:  Govind K Makharia
Journal:  Front Med (Lausanne)       Date:  2014-03-24

10.  Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology.

Authors:  Jonas F Ludvigsson; Julio C Bai; Federico Biagi; Timothy R Card; Carolina Ciacci; Paul J Ciclitira; Peter H R Green; Marios Hadjivassiliou; Anne Holdoway; David A van Heel; Katri Kaukinen; Daniel A Leffler; Jonathan N Leonard; Knut E A Lundin; Norma McGough; Mike Davidson; Joseph A Murray; Gillian L Swift; Marjorie M Walker; Fabiana Zingone; David S Sanders
Journal:  Gut       Date:  2014-06-10       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.